Radyus Research, a U.S.-based drug development organization, and Eurofins CDMO Alphora, a Canadian contract development and manufacturing organization, announced a new strategic partnership on May 28, 2025, to accelerate early-stage drug development for biotech companies worldwide. The collaboration integrates capabilities from preclinical development through clinical proof-of-concept to create a unified services offering aimed at reducing inefficiencies and improving drug program success rates.
Complementary Expertise and Capabilities
The partnership leverages the distinct strengths of both organizations to provide comprehensive drug development solutions. Radyus Research contributes deep expertise in drug development strategy, efficacy and safety animal testing, regulatory planning, clinical trial operations, and cross-functional program management. Eurofins CDMO Alphora serves as the partnership's manufacturing engine, bringing a strong record in process development and GMP manufacturing for small molecule APIs, biologics, and drug products.
"We're excited to launch this partnership and unlock the value for our clients," said Marta New, CEO of Radyus Research. "It reflects our joint belief that long-term collaboration, rather than transactional engagement, is the key to efficient drug development. Together, we're surrounding our clients with a world-class, globally connected operating teams committed to delivering great results."
Focus on Long-Term Collaboration
The partnership is built on a shared commitment to operational R&D excellence through long-term client collaborations. By integrating their capabilities, Radyus and Alphora aim to help clients reduce inefficiencies, eliminate handoffs, and improve the likelihood of drug program success. This approach represents a shift from traditional transactional relationships toward sustained partnerships in the biopharmaceutical industry.
"This alliance with Radyus enhances our ability to deliver cohesive strategies and executional excellence across the development continuum," Eurofins CDMO Alphora noted. "Together, we're building a high-trust model that reflects the collaborative, global nature of today's biopharmaceutical industry."
Comprehensive Service Portfolio
Radyus Research specializes in integrated drug development, focusing on preclinical and early clinical program strategy, R&D operations, regulatory submissions, and cross-functional program management. The organization supports biotech companies from lead optimization through clinical validation of novel therapeutics and vaccines using a milestone-driven approach.
Eurofins CDMO Alphora delivers fully integrated process development and GMP manufacturing solutions for small molecule APIs, drug products, and biologics, supporting biopharmaceutical innovators from early development to commercialization. Enhanced by the scientific depth and geographic reach of the global Eurofins network of companies, Alphora provides clients with seamless access to advanced analytical services, bioanalysis, toxicology, clinical logistics, and biomarker discovery.
Industry Impact
The strategic alliance positions both companies to redefine early-stage drug development with a unified services solution that is integrated, international, and focused on long-term client success. The partnership addresses the growing need for streamlined drug development processes in an increasingly complex and competitive biopharmaceutical landscape, where efficiency and collaboration are critical for bringing innovative therapeutics to market.
